Effects of folic acid supplementation on inflammatory and thrombogenic markers in chronic smokers. A randomised controlled trial

Thrombosis Research

Volumn 110, Issue 1, 2003, Pages 13-17

  Mangoni, Arduino A ^a   Arya, Roopen ^a   Ford, Elizabeth ^a   Asonganyi, Belinda ^a   Sherwood, Roy A ^a   Ouldred, Emma ^a   Swift, Cameron G ^a   Jackson, Stephen H D ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Folic acid; Homocysteine; Inflammation; Smoking; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 8; D DIMER; FIBRINOGEN; FOLIC ACID; HOMOCYSTEINE; PLACEBO; VON WILLEBRAND FACTOR;

ADULT; BLOOD CLOTTING; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REDUCTION; SMOKING; THROMBOGENICITY; VITAMIN SUPPLEMENTATION;

EID: 0038107534     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(03)00295-0     Document Type: Conference Paper

References (33)

1. de Bree A., Verschuren W.M., Blom H.J., Kromhout D. Lifestyle factors and plasma homocysteine concentrations in a general population sample. Am. J. Epidemiol. 154:2001;150-154.
2. Koenig W., Sund M., Frohlich M., Fischer H.G., Lowel H., Doring A.et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 99:1999;237-242.
3. Mendall M.A., Patel P., Ballam L., Strachan D., Northfield T.C. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ. 312:1996;1061-1065.
4. Wallenfeldt K., Hulthe J., Bokemark L., Wikstrand J., Fagerberg B. Carotid and femoral atherosclerosis, cardiovascular risk factors and C-reactive protein in relation to smokeless tobacco use or smoking in 58-year-old men. J. Intern. Med. 250:2001;492-501.
5. Miller G.J., Bauer K.A., Cooper J.A., Rosenberg R.D. Activation of the coagulant pathway in cigarette smokers. Thromb. Haemost. 79:1998;549-553.
6. Tuut M., Hense H.W. Smoking, other risk factors and fibrinogen levels. Evidence of effect modification. Ann. Epidemiol. 11:2001;232-238.
7. Yarnell J.W.G., Sweetnam P.M., Rumley A., Lowe G.D.O. Lifestyle and hemostatic risk factors for ischemic heart disease. The Caerphilly Study. Arterioscler. Thromb. Vasc. Biol. 20:2000;271-279.
8. Hjemdahl P. Smoking, nicotine and thrombotic risk - a role for platelet dependent thrombin generation? Eur. Heart J. 22:2001;16-18.
9. Kuch B., Bobak M., Fobker M., Junker R., von Eckardstein A., Marmot M.et al. Associations between homocysteine and coagulation factors - a cross-sectional study in two populations of central Europe. Thromb. Res. 103:2001;265-273.
10. Lentz S.R., Sadler J.E. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J. Clin. Invest. 88:1991;1906-1914.
11. Harpel P.C., Zhang X., Borth W. Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis. J. Nutr. 126(4 Suppl.):1996;1285S-1289S.
12. Mangoni A.A., Jackson S.H.D. Homocysteine and cardiovascular disease: current concepts and future prospects. Am. J. Med. 112:2002;556-565.
13. Refsum H., Ueland P.M., Svardal A.M. Fully automated fluorescence assay for determining total homocysteine in plasma. Clin. Chem. 35:1989;1921-1927.
14. Midorikawa S., Sanada H., Hashimoto S., Watanabe T. Enhancement by homocysteine of plasminogen activator inhibitor-1 gene expression and secretion from vascular endothelial and smooth muscle cells. Biochem. Biophys. Res. Commun. 272:2000;182-185.
15. Khajuria A., Houston D.S. Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis. Blood. 96:2000;966-972.
16. Durand P., Lussier-Cacan S., Blache D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J. 11:1997;1157-1168.
17. Ragone R. Homocysteine solubility and vascular disease. FASEB J. 16:2002;401-404.
18. Mansoor M.A., Svardal A.M., Schneede J., Ueland P.M. Dynamic relation between reduced, oxidized, and protein-bound homocysteine and other thiol components in plasma during methionine loading in healthy men. Clin. Chem. 38:1992;1316-1321.
19. Guttormsen A.B., Mansoor A.M., Fiskerstrand T., Ueland P.M., Refsum H. Kinetics of plasma homocysteine in healthy subjects after perioral homocysteine loading. Clin. Chem. 39:1993;1390-1397.
20. Lowe G.D., Wood D.A., Douglas J.T., Riemersma R.A., Macintyre C.C., Takase T.et al. Relationships of plasma viscosity, coagulation and fibrinolysis to coronary risk factors and angina. Thromb. Haemost. 65:1991;339-343.
21. Cigarette smoking among adults-United States, 1999. MMWR. 50:2001;869-873.
22. Van Guldener C., Janssen M.J., Lambert J., ter Wee P.M., Jakobs C., Donker A.J.M.et al. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinemia in haemodialysis patients. Nephrol. Dial. Transplant. 13:1998;106-112.
23. Van Guldener C., Janssen M.J., Lambert J., ter Wee P.M., Donker A.J., Stehouwer C.D. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy. Perit. Dial. Int. 18:1998;282-289.
24. Thambyrajah J., Landray M.J., McGlynn F.J., Jones H.J., Wheeler D.C., Townend J.N. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? Circulation. 102:2000;871-875.
25. Mayer O., Šimon J., Rosolová H., Hromádka M., Šubrt I., Vobrubová I. The effects of folate supplementation on some coagulation parameters and oxidative status surrogates. Eur. J. Clin. Pharmacol. 58:2002;1-5.
26. Budisavljevic M.N., Cheek D., Ploth D.W. Calciphylaxis in chronic renal failure. J. Am. Soc. Nephrol. 7:1996;978-982.
27. Schulz E., Ruschitzka F., Lueders S., Heydenbluth R., Schrader J., Muller G.A. Effect of endothelin on hemodynamics, prostaglandins, blood coagulation and renal function. Kidney Int. 47:1995;795-801.
28. Osende J.I., Badimon J.J., Fuster V., Herson P., Rabito P., Vidhun R.et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J. Am. Coll. Cardiol. 38:2001;1307-1312.
29. Verhaar M.C., Wever R.M.F., Kastelein J.J.P., van Dam T., Koomans H.A., Rabelink T.J. 5-Methyltetrahydrofolate, the active form of folic acid, improves endothelial function in familial hypercholesterolemia. Circulation. 97:1998;237-241.
30. Doshi S.N., McDowell I.F., Moat S.J., Lang D., Newcombe R.G., Kredan M.B.et al. Folate improves endothelial function in coronary heart disease: an effect mediated by reduction of intracellular superoxide? Arterioscler. Thromb. Vasc. Biol. 21:2001;1196-1202.
31. Durand P., Prost M., Blache D. Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyinsaturated fatty acids. Atherosclerosis. 121:1996;231-243.
32. Stroes E., Hijmering M., van Zandvoort M., Wever R., Rabelink T.J., van Faassen E.E. Origin of superoxide production by endothelial nitric oxide synthase. FEBS Lett. 438:1998;161-164.
33. Stroes E.S.G., van Faessen E.E., Yo M., Martasek P., Boer P., Govers R.et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ. Res. 86:2000;1129-1134.